Prof. Dr. Marianne van der Steen is Professor of Entrepreneurship in Healthcare at the Technology-inspired Institute of Regenerative Medicine (MERLN), Faculty of Health, Medicine and Life Sciences, Maastricht University. She has been the General Director of RegMed XB from 2016-2020 and a member of the board of governors of RegMed XB foundation. Marianne van der Steen received her Ph.D. degree in 1999 from Twente University. Her research focus is on biomedical entrepreneurship, specifically on the scaling-up of ventures.
At MERLN, she is responsible for biomedical entrepreneurship valorization, training, and education from the lab to a spin-off company. In addition, she is the founding director of executive life sciences entrepreneurship programs such as the Global Investor Forum, the Global Scale-up Program, and the executive Master MBI Life Sciences & Health (currently member of the advisory board). Since 2006, she has been involved in life sciences start-ups, served in early-stage start-up investor boards and national and international advisory boards related to entrepreneurship and valorization in the Netherlands, Belgium, and the United States.
Rob de Ree is Chair of valorization at the Dutch Cardiovascular Alliance (DCVA), co-manager along RegMed XB of FIRST, a joint early phase investment fund. Rob started his career in pharma in 1991 in sales and marketing at the cardiovascular division of Byk Gulden. Rob joined Medtronic in 1996 where he worked in various sales and marketing roles, and then he moved to Crucell where he led the licensing business after which he joined BMEYE, a startup in hemodynamic monitoring where he serves as CEO until it was sold to Edwards Lifesciences.Rob was subsequently CEO of Dezima Pharma, which was sold to Amgen in October 2015. Currently, Rob is operating partner at Biogeneration Ventures since 2016, serving on the board and in interim management positions in the fund’s portfolio companies. In addition, he is CEO of NorthSea Therapeutics and serves on the board of Mellon Medical.
Maria Sol Cabrera is an Impact Officer at RegMed XB. She obtained a master’s degree in mechanical engineering from the National University of Mar del Plata and continued her academic career pursuing a master’s degree in material science at the Polytechnic University of Catalonia and the Technical University of Luleå. In 2015 she obtained a Ph.D. degree from the Technical University of Eindhoven in the field of stent design and became a LifeScience entrepreneur, co-founding and directing a start-up company dedicated to the development of regenerative stents
Margien Boels is an Impact Officer at the Dutch Cardiovascular Alliance (DCVA), where she’s responsible for the commercialization & valorization of DCVA consortia into solutions for patients and scalable biomed start-ups. She obtained a master’s degree in Nutrition and Health from Wageningen University and continued her academic career pursuing a Ph.D. degree in Medicine from Leiden University Medical Center in 2016 with the project “The glomerular endothelial glycocalyx in diabetic nephropathy, as part of a consortium of the Dutch Kidney Foundation. Later one, she worked as a stakeholder manager and as a Medical affairs Manager for Nutricia Nederland Medical.
Tom Mastenbroek is Impact Officer & Project Manager for RegMedXB. He studied biology at the University of Wageningen and during his master’s education he specialized in cellular differentiation and immunology. In 2016, he obtained his Ph.D. in the field of vascular biology, vessel wall remodelling and thrombosis & haemostasis at Maastricht University under the guidance of Dr. Judith Cosemans and Prof. Johan Heemskerk. In his thesis, he showed for the first time the potential of blood platelets to degrade extracellular matrix and the involvement of platelets in pathological remodelling of the vessel wall after an atherothrombotic event. This concept was further exploited during his PostDoc where he identified novel ways of inhibiting platelet dependent growth factor secretion aiming to block pathological vascular remodelling.